PHARMACOLOGIC EFFECTS ON MITOCHONDRIAL FUNCTION

被引:35
作者
Cohen, Bruce H. [1 ]
机构
[1] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44195 USA
关键词
mitochondria; drug toxicity; oxidative phosphorylation; mitochondrial DNA; POLG; inner mitochondrial membrane; free radicals; DNA-POLYMERASE-GAMMA; COMPLEX-I; PERMEABILITY TRANSITION; ANTIRETROVIRAL THERAPY; POLG MUTATIONS; GENE-MUTATIONS; HEARING-LOSS; TOXICITY; NUCLEOSIDE; VALPROATE;
D O I
10.1002/ddrr.106
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The vast majority of energy necessary for cellular function is produced in mitochondria. Free-radical production and apoptosis are other critical mitochondrial functions. The complex structure, electrochemical properties of the inner mitochondrial membrane (IMM), and genetic control from both mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) are some of the unique features that explain why the mitochondria are vulnerable to environmental injury. Because of similarity to bacterial translational machinery, mtDNA translation is likewise vulnerable to inhibition by some antibiotics. The mechanism of mtDNA replication, which is required for normal mitochondrial maintenance and duplication, is inhibited by a relatively new class of drugs used to treat AIDS. The electrochemical gradient maintained by the IMM is vulnerable to many drugs that are weak organic acids at physiological pH, resulting in excessive free-radical generation and uncoupling of oxidative phosphorylation. Many of these drugs can cause clinical injury in otherwise healthy people, but there are also examples where particular gene mutations may predispose to increased drug toxicity. The spectrum of drug-induced mitochondrial dysfunction extends across many drug classes. It is hoped that preclinical pharmacogenetic and functional studies of mitochondrial toxicity, along with personalized genomic medicine, will improve both our understanding of mitochondrial drug toxicity and patient safety. (C) 2010 Wiley-Liss, Inc. Dev Disabil Res Rev 2010;16:189-199.
引用
收藏
页码:189 / 199
页数:11
相关论文
共 111 条
[41]  
HOLT IJ, 1990, AM J HUM GENET, V46, P428
[42]   Cardiolipin, the heart of mitochondrial metabolism [J].
Houtkooper, R. H. ;
Vaz, F. M. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2008, 65 (16) :2493-2506
[43]   Mitochondrial DNA polymerase-γ and human disease [J].
Hudson, Gavin ;
Chinnery, Patrick F. .
HUMAN MOLECULAR GENETICS, 2006, 15 :R244-R252
[44]   Sensorineural hearing loss and the 1555G mitochondrial DNA mutation [J].
Hutchin, T .
ACTA OTO-LARYNGOLOGICA, 1999, 119 (01) :48-52
[45]   Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity [J].
Kakuda, TN .
CLINICAL THERAPEUTICS, 2000, 22 (06) :685-708
[46]   Mitochondrial permeability transition in the switch from necrotic to apoptotic cell death in ischemic rat hepatocytes [J].
Kim, JS ;
Qian, T ;
Lemasters, JJ .
GASTROENTEROLOGY, 2003, 124 (02) :494-503
[47]  
Lamb T.D., 1990, Seminars in the Neurosciences, V2, P3
[48]   2',3'-DIDEOXYINOSINE (DDI) IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME OR AIDS-RELATED COMPLEX - A PHASE-I TRIAL [J].
LAMBERT, JS ;
SEIDLIN, M ;
REICHMAN, RC ;
PLANK, CS ;
LAVERTY, M ;
MORSE, GD ;
KNUPP, C ;
MCLAREN, C ;
PETTINELLI, C ;
VALENTINE, FT ;
DOLIN, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (19) :1333-1340
[49]  
LEFRAK EA, 1973, CANCER-AM CANCER SOC, V32, P302, DOI 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO
[50]  
2-2